Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page

    Successful treatment of COVID-19 MESHD with remdesivir in the absence of humoral immunity

    Authors: Matthew S Buckland; James Galloway; Caoimhe Nic Fhogartaig; Luke Meredith; Nicholas M. Provine; Stuart Bloor; Ane Ogbe; Wioleta M. Zelek; Anna Smielewska; Anna Yakovleva; Tiffeney Mann; Laura Bergamaschi; Lorinda Turner; Frederica Mescia; Erik J.M. Toonen; Carl-Philipp Hackstein; Hossain Delowar Akther; Vinicius Adriano Vieira; Lourdes Ceron-Gutierrez; Jimstan Periselneris; Sorena Kiani-Alikhan; Sofia Grigoriadou; Devan Vaghela; Sara E. Lear; Estee Torok; William L. Hamilton; Josh Quick; Joanne Stockton; Peter Nelson; Michael Hunter; Tanya I Coulter; Lisa Devlin; John Bradley; Ken Smith; Willem Ouwehand; Lise Estcourt; Heli Harvala Simmonds; Dave Roberts; Ian Wilkinson; Nick Screaton; Nick Loman; Paul Lyons; Rainer Doffinger; Paul Morgan; Ian Goodfellow; Paul Klenerman; Paul Lehner; Nick Matheson; James Thaventhiran

    doi:10.21203/ Date: 2020-09-16 Source: ResearchSquare

    The response to the coronavirus disease 2019 MESHD ( COVID-19 MESHD) pandemic has been hampered by lack of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral therapy. Here we report the successful use of remdesivir in a patient with COVID-19 MESHD and the prototypic genetic antibody deficiency X-linked agammaglobulinaemia MESHD X-linked agammaglobulinaemia (XLA) HGNC. Despite evidence of complement activation and a robust T cell response, the patient developed persistent SARS-CoV-2 pneumonitis MESHD, without progressing to multi-organ involvement. His unusual clinical course identifies a key role for SARS-CoV-2 antibodies in both viral clearance and progression to severe disease. In the absence of these confounders, we took an experimental medicine approach to examine the in vivoutility of remdesivir. Over two independent courses of treatment, we observed a dramatic, temporally correlated clinical and virological response, leading to clinical resolution and viral clearance, with no evidence of acquired drug resistance. We therefore provide unambiguous evidence for the antiviral efficacy of remdesivir in vivo, and its potential benefit in selected patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.